Considering the low toxicity of PSMA-targeted RLT [55], further preclinical and clinical investigations are warranted to define a PSMA-targeted theragnostic approach in HCC, using PSMA-targeted compounds radiolabeled with beta- or alpha-emitting radionuclides, and simultaneously examine the crossfire effect and radiotoxicity of beta emitters in the healthy liver tissue. Here, FOLH1 is linked to hepatocellular carcinoma.